Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer
Biodesix, Inc. (BDSX)
Company Research
Source: Business Wire
Data published shows the VeriStrat proteomic test improved overall patient survival by better informing physicians on the selection of immunotherapies to optimally treat NSCLC patients BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) utilizing its novel predictive and prognostic blood-based host immune classifier (the VeriStrat test) to stratify Immune checkpoint inhibition (ICI) treatment response in patients with advanced non-small cell lung cancer(NSCLC). The study, titled “Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer,” was published in the Journal of Immunotherapy
Show less
Read more
Impact Snapshot
Event Time:
BDSX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDSX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDSX alerts
High impacting Biodesix, Inc. news events
Weekly update
A roundup of the hottest topics
BDSX
News
- Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024Business Wire
- The recent US$4.0m market cap decrease is likely to have disappointed insiders invested in Biodesix, Inc. (NASDAQ:BDSX) [Yahoo! Finance]Yahoo! Finance
- Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual MeetingBusiness Wire
BDSX
Earnings
- 3/1/24 - In-Line
BDSX
Analyst Actions
- 3/4/24 - Canaccord Genuity
BDSX
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- BDSX's page on the SEC website